After being awarded the Joel M. Dalrymple award for best presentation in Workshop 15 (Bunyaviruses: Pathogenesis and vaccines) at the American Society for Virology meeting earlier this year, the corresponding paper of Paul Wichgers Schreur was selected by the Editors of Journal of Virology as an “Article of Significant Interest” and was placed in the “Spotlight” of the Journal of Virology. The studies of Paul yielded novel insights into the mechanism of bunyavirus genome packaging as well as a novel technology to develop live-attenuated bunyavirus vaccines. A novel RVFV vaccine, developed with this technology, was shown to be completely safe for animals and to induce sterile immunity after a single vaccination.
Rift Valley fever virus (RVFV) is a mosquito-transmitted bunyavirus that causes serious disease in livestock and occasionally humans. The virus is currently largely confined to the African continent, but the virus continues to expand its present habitat. CVI plays a world-leading role in vaccine development against this deadly pathogen.